参考文献/References:
[1] KLEIN M J,SIEGAL G P.Osteosarcoma: Anatomic and histologic variants[J].American Journal of Clinical Pathology,2006,125(4):555-581.DOI:10.1309/UC6K-QHLD-9LV2-KENN.
[2] SMELAND S,BIELACK S S,WHELAN J,et al.Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1(European and American Osteosarcoma Study)cohort[J].European Journal of Cancer,2019,109:36-50.DOI:10.1016/j.ejca.2018.11.027.
[3] MILLER B J,CRAM P,LYNCH C F,et al.Risk factors for metastatic disease at presentation with osteosarcoma: An analysis of the SEER database[J].The Journal of Bone and Joint Surgery. American Volume,2013,95(13):e89.DOI:10.2106/JBJS.L.01189.
[4] NIE Zhigang,PENG Hao.Osteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes[J].Oncology Letters,2018,16(5):6502-6514.DOI:10.3892/ol.2018.9453.
[5] ALFRANCA A,MARTINEZ-CRUZADO L,TORNIN J,et al.Bone microenvironment signals in osteosarcoma development[J].Cellular and Molecular Life Sciences,2015,72(16):3097-3113.DOI:10.1007/s00018-015-1918-y.
[6] MATHIEU M,MARTIN-JAULAR L,LAVIEU G,et al.Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication[J].Nature Cell Biology,2019,21(1):9-17.DOI:10.1038/s41556-018-0250-9.
[7] ZHANG Bin,ZHANG Yan,LI Rongzhen,et al.The efficacy and safety comparison of first-line chemotherapeutic agents(high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide)for osteosarcoma: A network meta-analysis[J].Journal of Orthopaedic Surgery and Research,2020,15(1):51.DOI:10.1186/s13018-020-1576-0.
[8] WAGLEY Y,CHESI A,ACEVEDO P K,et al.Canonical notch signaling is required for bone morphogenetic protein-mediated human osteoblast differentiation[J].Stem Cells,2020,38(10):1332-1347.DOI:10.1002/stem.3245.
[9] FENG Weilou,WANG Zhi,FENG Dongxu,et al.The effects of common variants in MDM2 and GNRH2 genes on the risk and survival of osteosarcoma in Han populations from Northwest China[J].Scientific Reports,2020,10(1):15939.DOI:10.1038/s41598-020-72995-4.
[10] MA J,KLEMM J,GERARDO-RAMIREZ M,et al.Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin[J].International Journal of Cancer,2020,147(9):2564-2577.DOI:10.1002/ijc.33144.
[11] TOUS-ROMERO F,PALMA-MILLA C,ORTIZ-DE FRUTOS J.Skin lesions associated with a new mutation in the RECQL4 gene in a patient with osteosarcoma[J].Actas Dermo-Sifiliográficas,2022,113(10):983-984.DOI:10.1016/j.ad.2021.07.013.
[12] ZHANG Ying,LIU Zhaoyong,YANG Xia,et al.H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts[J].Theranostics,2021,11(3):1473-1492.DOI:10.7150/thno.51245.
[13] ZHU Shutao,LIU Yang,WANG Xiao,et al.lncRNA SNHG10 promotes the proliferation and invasion of osteosarcoma via Wnt/β-catenin signaling[J].Molecular Therapy-Nucleic Acids,2020,22:957-970.DOI:10.1016/j.omtn.2020.10.010.
[14] LIU Jianmin,CHEN Ming,MA Longyang,et al.LncRNA GAS5 suppresses the proliferation and invasion of osteosarcoma cells via the miR-23a-3p/PTEN/PI3K/AKT pathway[J].Cell Transplant,2020,29:963689720953093.DOI:10.1177/0963689720953093.
[15] WANG Shenglin,WANG Yunqing,HUANG Zhen,et al.Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway[J].Acta Biochim Biophys Sin(Shanghai),2021,53(12):1670-1680.DOI:10.1093/abbs/gmab146.
[16] LI Rui,SHI Yanlong,ZHAO Shiwei,et al.NF-κB signaling and integrin-β1 inhibition attenuates osteosarcoma metastasis via increased cell apoptosis[J].International Journal of Biological Macromolecules,2019,123:1035-1043.DOI:10.1016/j.ijbiomac.2018.11.003.
[17] NING Lei,WAN Shuanglin,JIE Zhiwei,et al.Lycorine induces apoptosis and G1 phase arrest through ROS/p38 MAPK signaling pathway in human osteosarcoma cells in vitro and in vivo[J].Spine,2020,45(3):E126-E139.DOI:10.1097/brs.0000000000003217.
[18] YUAN Putao,FENG Zhenhua,HUANG Hai,et al.USP1 inhibition suppresses the progression of osteosarcoma via destabilizing TAZ[J].International Journal of Biological Sciences,2022,18(8):3122-3136.DOI:10.7150/ijbs.65428.
[19] CHEN Fangyu,CHEN Liuwei,QIN Qin,et al.Salt-inducible kinase 2: An oncogenic signal transmitter and potential target for cancer therapy[J].Frontiers in Oncology,2019,9:18.DOI:10.3389/fonc.2019.00018.
[20] ZENG Qiuming,LI Zongyuan,ZHAO Xi,et al.Ubiquitin specific protease 7 promotes osteosarcoma cell metastasis by inducing epithelia mesenchymal transition[J].Oncology Reports,2018,41(1):543-551.DOI:10.3892/or.2018.6835.
[21] BHANUMATHY K K,BALAGOPAL A,VIZEACOUMAR F S,et al.Protein tyrosine kinases: Their roles and their targeting in leukemia[J].Cancers,2021,13(2):184.DOI:10.3390/cancers13020184.
[22] HUANG Zhen,WANG Shenglin,CHEN Hui,et al.Clinicopathological and prognostic values of ErbB receptor family amplification in primary osteosarcoma[J].Scandinavian Journal of Clinical and Laboratory Investigation,2019,79(8):601-612.DOI:10.1080/00365513.2019.1683764.
[23] JULLIEN N,DIEUDONNE F X,HABEL N,et al.ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo[J].Gene,2013,521(1):55-61.DOI:10.1016/j.gene.2013.03.031.
[24] SONG Lei,DUAN Ping,GAN Yibo,et al.Silencing LPAATβ inhibits tumor growth of cisplatin-resistant human osteosarcoma in vivo and in vitro[J].International Journal of Oncology,2017,50(2):535-544.DOI:10.3892/ijo.2016.3820.
[25] GAN Yu,WANG Yong,TAN Zhengyu,et al.TDRG1 regulates chemosensitivity of seminoma TCam-2 cells to cisplatin via PI3K/Akt/mTOR signaling pathway and mitochondria-mediated apoptotic pathway[J].Cancer Biology & Therapy,2016,17(7):741-750.DOI:10.1080/15384047.2016.1178425.
[26] CAO Junjie,WEI Yalin,LIAN Jing,et al.Notch signaling pathway promotes osteogenic differentiation of mesenchymal stem cells by enhancing BMP9/Smad signaling[J].International Journal of Molecular Medicine,2017,40(2):378-788.DOI:10.3892/ijmm.2017.3037.
[27] MARTINO J S D,AKHTER T,BRAVO-CORDERO J J.Remodeling the ECM: Implications for metastasis and tumor dormancy[J].Cancers(Basel),2021,13(19):4916.DOI:10.3390/cancers13194916.
[28] BERGAMASCHI A,TAGLIABUE E,SORLIE T,et al.Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome[J].The Journal of Pathology,2008,214(3):357-367.DOI:10.1002/path.2278.
[29] ZHANG Yongtao,WANG Fang,WANG Lina,et al.MiR-363 suppresses cell migration, invasion, and epithelial-mesenchymal transition of osteosarcoma by binding to NOB1[J].World Journal of Surgical Oncology,2020,18(1):83.DOI:10.1186/s12957-020-01859-y.
[30] SUMAIYA K,LANGFORD D,NATARAJASEENIVASAN K,et al.Macrophage migration inhibitory factor(MIF): A multifaceted cytokine regulated by genetic and physiological strategies[J].Pharmacology & Therapeutics,2022,233:108024.DOI:10.1016/j.pharmthera.2021.108024.
[31] CENTOMO M L,VITIELLO M,POLISENO L,et al.An immunocompetent environment unravels the proto-oncogenic role of miR-22[J].Cancers(Basel),2022,14(24):6255.DOI:10.3390/cancers14246255.
[32] LIAN Hongyu,ZHOU Yang,SUN Zhang,et al.MicroRNA34a is associated with chemotherapy resistance, metastasis, recurrence, survival, and prognosis in patient with osteosarcoma[J].Medicine,2022,101(38):e30722.DOI:10.1097/md.0000000000030722.
[33] FANG Xiaoguang,HUANG Zhi,ZHAI Kui,et al.Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice[J].Science Translational Medicine,2021,13(600):eabc7275.DOI:10.1126/scitranslmed.abc7275.
[34] GU Qingguo,LUO Yibin,CHEN Cheng,et al.GREM1 overexpression inhibits proliferation, migration and angiogenesis of osteosarcoma[J].Experimental Cell Research,2019,384(1):111619.DOI:10.1016/j.yexcr.2019.111619.
[35] SUN Yao,LIU Guoliang,ZHANG Kai,et al.Stem cell-derived exosomes: Emerging therapeutic opportunities for wound healing[J].Stem Cell Research & Therapy,2023,14(1):107.DOI:10.1186/s13287-023-03345-0.
[36] ZHOU Chuchao,ZHANG Boyu,YANG Yanqing,et al.Mesenchymal stem cells-derived exosomes for drug delivery[J].Stem Cell Research & Therapy,2021,12(1):561.DOI:10.1186/s13287-021-02629-7.
[37] ABDELMONEIM M,EL-NAENAEEY E Y,ABD-ALLAH S H,et al.Anti-inflammatory and immunomodulatory role of bone marrow-derived MSCs in mice with acute lung injury[J].Journal of Interferon & Cytokine Research,2021,41(1):29-36.DOI:10.1089/jir.2020.0073.
[38] QIAO Ling,XU Zhili,ZHAO Tiejun,et al.Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling[J].Cancer Letters,2008,269(1):67-77.DOI:10.1016/j.canlet.2008.04.032.
[39] KARNOUB A E,DASH A B,VO A P,et al.Mesenchymal stem cells within tumour stroma promote breast cancer metastasis[J].Nature,2007,449(7162):557-563.DOI:10.1038/nature06188.
[40] JOHNSTONE R M,ADAM M,HAMMOND J R,et al.Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles(exosomes)[J].Journal of Biological Chemistry,1987,262(19):9412-9420.DOI:10.1016/s0021-9258(18)48095-7.
[41] ZHANG Yi,BI Jiayao,HUANG Jiayi,et al.Exosome: A review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications[J].International Journal of Nanomedicine,2020,15(69):17-34.DOI:10.2147/IJN.S264498.
[42] KOGURE A,YOSHIOKA Y,OCHIYA T.Extracellular vesicles in cancer metastasis: Potential as therapeutic targets and materials[J].International Journal of Molecular Sciences,2020,21(12):4463.DOI:10.3390/ijms211 24463.
[43] GIMONA M,BRIZZI M F,CHOO A B H,et al.Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles[J].Cytotherapy,2021,23(5):373-380.DOI:10.1016/j.jcyt.2021.01.001.
[44] BAGNO L,HATZISTERGOS K E,BALKAN W,et al.Mesenchymal stem cell-based therapy for cardiovascular disease: Progress and challenges[J].Molecular Therapy,2018,26(7):1610-1623.DOI:10.1016/j.ymthe.2018.05.009.
[45] YAGHOUBI Y,MOVASSAGHPOUR A,ZAMANI M,et al.Human umbilical cord mesenchymal stem cells derived-exosomes in diseases treatment[J].Life Sciences,2019,233:116733.DOI:10.1016/j.lfs.2019.116733.
[46] HASSANZADEH A,RAHMAN H S,MARKOV A,et al.Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities[J].Stem Cell Research & Therapy,2021,12(1):297.DOI:10.1186/s13287-021-02378-7.
[47] B?RGER V,BREMER M,FERRER-TUR R,et al.Mesenchymal stem/stromal cell-derived extracellular vesicles and their potential as novel immunomodulatory therapeutic agents[J].International Journal of Molecular Sciences,2017,18(7):1450.DOI:10.3390/ijms18071450.
[48] WANG Jingjing,SUN Zhen,GOU Wenyu,et al.Alpha-1 antitrypsin enhances islet engraftment by suppression of instant blood-mediated inflammatory reaction[J].Diabetes,2017,66(4):970-980.DOI:10.2337/db16-1036.
[49] KANG I S,SUH J,LEE M N,et al.Characterization of human cardiac mesenchymal stromal cells and their extracellular vesicles comparing with human bone marrow derived mesenchymal stem cells[J].BMB Reports,2020,53(2):118-123.DOI:10.5483/BMBRep.2020.53.2.235.
[50] VAKHSHITEH F,ATYABI F,OSTAD S N.Mesenchymal stem cell exosomes: A two-edged sword in cancer therapy[J].International Journal of Nanomedicine,2019,14:2847-2859.DOI:10.2147/IJN.S200036.
[51] YANG Xucheng,YANG Junxiao,LEI Pengfei,et al.LncRNA MALAT1 shuttled by bone marrow-derived mesenchymal stem cells-secreted exosomes alleviates osteoporosis through mediating microRNA-34c/SATB2 axis[J].Aging,2019,11(20):8777-8791.DOI:10.18632/aging.102264.
[52] ZUO Rui,LIU Minghan,WANG Yanqiu,et al.BM-MSC-derived exosomes alleviate radiation-induced bone loss by restoring the function of recipient BM-MSCs and activating Wnt/beta-catenin signaling[J].Stem Cell Research & Therapy,2019,10(1):30.DOI:10.1186/s13287-018-1121-9.
[53] ZHANG Lu,JIAO Guangjun,REN Shanwu,et al.Exosomes from bone marrow mesenchymal stem cells enhance fracture healing through the promotion of osteogenesis and angiogenesis in a rat model of nonunion[J].Stem Cell Research & Therapy,2020,11(1):38.DOI:10.1186/s13287-020-1562-9.
[54] ZHA Yao,LI Yawu,LIN Tianyi,et al.Progenitor cell-derived exosomes endowed with VEGF plasmids enhance osteogenic induction and vascular remodeling in large segmental bone defects[J].Theranostics,2021,11(1):397-409.DOI:10.7150/thno.50741.
[55] ZHANG Bin,LAI R C,SIM W K,et al.Topical application of mesenchymal stem cell exosomes alleviates the imiquimod induced psoriasis-like inflammation[J].International Journal of Molecular Sciences,2021,22(2):720.DOI:10.3390/ijms22020720.
[56] ZHAO Yangmin,GAN Yunxiao,XU Gewei,et al.MSCs-derived exosomes attenuate acute brain injury and inhibit microglial inflammation by reversing CysLT2R-ERK1/2 mediated microglia M1 polarization[J].Neurochemical Research,2020,45(5):1180-1190.DOI:10.1007/s11064-020-02998-0.
[57] LIU Kai,CAI Guoliang,ZHUANG Zhe,et al.Interleukin-1β-treated mesenchymal stem cells inhibit inflammation in hippocampal astrocytes through exosome-activated nrf-2 signaling[J].International Journal of Nanomedicine,2021,16:1423-1434.DOI:10.2147/IJN.S289914.
[58] YOSHIDA A,FUJIWARA T,UOTANI K,et al.Clinical and functional significance of intracellular and extracellular microRNA-25-3p in osteosarcoma[J].Acta Med Okayama,2018,72(2):165-174.DOI:10.18926/AMO/55857.
[59] SHIMBO K,MIYAKI S,ISHITOBI H,et al.Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration[J].Biochemical and Biophysical Research Communications,2014,445(2):381-387.DOI:10.1016/j.bbrc.2014.02.007.
[60] QIN Fa,TANG Haoyu,ZHANG Yong,et al.Bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-208a promotes osteosarcoma cell proliferation, migration, and invasion[J].Journal of Cellular Physiology,2020,235(5):4734-4745.DOI:10.1002/jcp.29351.
[61] ZHANG Hongliang,WANG Jun,REN Tingting,et al.Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B[J].Cancer Letters,2020,490:54-65.DOI:10.1016/j.canlet.2020.07.008.
[62] GONG Liangzhi,BAO Qiyuan,HU Chuanzhen,et al.Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1[J].Biochemical and Biophysical Research Communications,2018,500(2):170-176.DOI:10.1016/j.bbrc.2018.04.016.
[63] RUAN Qing,WANG Cuijie,WU Yuntao,et al.Exosome microRNA-22 inhibiting proliferation, migration and invasion through regulating Twist1/CADM1 axis in osteosarcoma[J].Scientific Reports,2024,14(1):761.DOI:10.1038/s41598-023-50612-4.
[64] YUN Chao,ZHANG Jincai,MORIGELE.MiR-488-3p represses malignant behaviors and facilitates autophagy of osteosarcoma cells by targeting neurensin-2[J].Current Pharmaceutical Biotechnology,2024,25(10):1264-1275.DOI:10.2174/1389201024666230626102837.
[65] XU Zhengfeng,ZHOU Xiaoxiao,WU Jiajun,et al.Mesenchymal stem cell-derived exosomes carrying microRNA-150 suppresses the proliferation and migration of osteosarcoma cells via targeting IGF2BP1[J].Translational Cancer Research,2020,9(9):5323-5335.DOI:10.21037/tcr-20-83.
[66] ZHAO Wei,QIN Pan,ZHANG Da,et al.Long non-coding RNA PVT1 encapsulated in bone marrow mesenchymal stem cell-derived exosomes promotes osteosarcoma growth and metastasis by stabilizing ERG and sponging miR-183-5p[J].Aging,2019,11(21):9581-9596.DOI:10.18632/aging.102406.
[67] LI Fujiang,CHEN Xin,SHANG Cong,et al.Bone marrow mesenchymal stem cells-derived extracellular vesicles promote proliferation, invasion and migration of osteosarcoma cells via the lncRNA MALAT1/miR-143/NRSN2/Wnt/beta-catenin axis[J].OncoTargets and Therapy,2021,14:737-749.DOI:10.2147/OTT.S283459.
[68] ENDO-MUNOZ L,CAI N,CUMMING A,et al.Progression of osteosarcoma from a non-metastatic to a metastatic phenotype is causally associated with activation of an autocrine and paracrine uPA axis[J].PLoS One,2015,10(8):e0133592.DOI:10.1371/journal.pone.0133592.
[69] GE Xuhui,LIU Wei,ZHAO Wene,et al.Exosomal transfer of LCP1 promotes osteosarcoma cell tumorigenesis and metastasis by activating the JAK2/STAT3 signaling pathway[J].Molecular Therapy-Nucleic Acids,2020,21:900-915.DOI:10.1016/j.omtn.2020.07.025.
[70] TANG Zhaopeng,LU Yubao,CHEN Yutong,et al.Research progress of microRNA in chemotherapy resistance of osteosarcoma[J].Technology in Cancer Research & Treatment,2021,20:15330338211034262.DOI:10.1177/15330338211034262.
[71] ZHU Kunpeng,MA Xiaolong,ZHANG Chunlin.Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1[J].International Journal of Biological Sciences,2018,14(3):321-330.DOI:10.7150/ijbs.24360.
[72] PU Youguang,ZHAO Fangfang,LI Yinpeng,et al.The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene[J].BMC Cancer,2017,17(1):45.DOI:10.1186/s12885-016-3002-x.
[73] WANG Lei,CHEN Yan,JIANG Ya,et al.MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4[J].BMC Cancer,2018,18(1):631.DOI:10.1186/s12885-018-4460-0.
[74] WANG Lin,TANG Bing,HAN Heng,et al.miR-155 affects osteosarcoma MG-63 cell autophagy induced by adriamycin through regulating PTEN-PI3K/AKT/mTOR signaling pathway[J].Cancer Biotherapy & Radiopharmaceuticals,2018,33(1):32-38.DOI:10.1089/cbr.2017.2306.
[75] LI Yi,SONG Xinmao,LIU Zegang,et al.Upregulation of miR-214 induced radioresistance of osteosarcoma by targeting PHLDA2 via PI3K/Akt signaling[J].Frontiers in Oncology,2019,9:298.DOI:10.3389/fonc.2019.00298.
[76] ABELLO J,NGUYEN T D T,MARASINI R,et al.Biodistribution of gadolinium-and near infrared-labeled human umbilical cord mesenchymal stromal cell-derived exosomes in tumor bearing mice[J].Theranostics,2019,9(8):2325-2345.DOI:10.7150/thno.30030.
[77] CHEN Lan,WANG Li,ZHU Lingling,et al.Exosomes as drug carriers in anti-cancer therapy[J].Frontiers in Cell and Developmental Biology,2022,10:728616.DOI:728616.10.3389/fcell.2022.728616.
[78] WEI Hongxiang,CHEN Fei,CHEN Jinyuan,et al.Mesenchymal stem cell derived exosomes as nanodrug carrier of doxorubicin for targeted osteosarcoma therapy via SDF1-CXCR4 Axis[J].International Journal of Nanomedicine,2022,17:3483-3495.DOI:10.2147/IJN.S372851.
[79] BENJAMIN R S.Adjuvant and neoadjuvant chemotherapy for osteosarcoma: A historical perspective[J].Advances in Experimental Medicine and Biology,2020,1257:1-10.DOI:10.1007/978-3-030-43032-0_1.
[80] WEI Hongxiang,CHEN Fei,CHEN Jinyuan,et al.A nanodrug consisting of doxorubicin and exosome derived from mesenchymal stem cells for osteosarcoma treatment in vitro[J].International Journal of Nanomedicine,2019,14:8603-8610.DOI:10.2147/IJN.S218988.
[81] WANG Jinkui,LI Mujie,JIN Liming,et al.Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma in vitro and in vivo[J].Drug Delivery,2022,29(1):3291-3303.DOI:10.1080/10717544.2022.2141921.
[82] KANCHANAPALLY R,KHAN M A,DESHMUKH S K,et al.Exosomal formulation escalates cellular uptake of honokiol leading to the enhancement of its antitumor efficacy[J].ACS Omega,2020,5(36):23299-23307.DOI:10.1021/acsomega.0c03136.
[83] NOOSHABADI V T,KHANMOHAMMADI M,SHAFEI S,et al.Impact of atorvastatin loaded exosome as an anti-glioblastoma carrier to induce apoptosis of U87 cancer cells in 3D culture model[J].Biochemistry and Biophysics Reports,2020,23:100792.DOI:10.1016/j.bbrep.2020.100792.
[84] ABAS B I,DEMIRBOLAT G M,CEVIK O.Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel[J].PLoS One,2022,17(9):e0274607.DOI:10.1371/journal.pone.0274607.